SImplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug regimen,researchers reported on Monday at theInternational Congress on Drug Therapy in HIV Infection (HIV Glasgow).
The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional comments and are notably cautious about not over-interpreting a study that only had 400 participants – very small for a prevention study – and an average of nine months’ follow-up.
It is the first, and so far only. randomised study to show that PrEP can be just as effective if it is given as an intermittent regimen that users only take when anticipating sex, rather than daily.